Newly Updated Cenestin.com Web Site Now Available
CINCINNATI, Mar 30, 2001 /PRNewswire via COMTEX/ -- Duramed Pharmaceuticals,
Inc. (Nasdaq: DRMD) announced today that an updated version of the web site for
its Cenestin(R) (synthetic conjugated estrogens, A) Tablets has been launched.
The site's URL is cenestin.com .
The new version of Cenestin.com site integrates the design of Cenestin's current
physician and patient promotional campaigns. Cenestin is co-marketed by Duramed
and Solvay Pharmaceuticals, Inc.
"Cenestin, with its smooth, steady delivery of conjugated estrogens, represents
one of the most important technological advances in estrogen replacement therapy
in the last 50 years," said Jim Hynd, Vice President of Marketing for Solvay
Pharmaceuticals, Inc. "Today's menopausal woman is information-savvy and is
always searching for additional educational resources on newer treatment
options. We believe the new Cenestin.com web site will help meet that
educational need in a user-friendly, technologically-advanced format."
Jeffrey T. Arington, Duramed President and Chief Operating Officer, said, "The
revised Cenestin.com is highly-informative electronic accompaniment to the
current Cenestin print campaign, increasing the synergy of the product's
promotion. The new site is an interactive way for women and their physicians to
learn about the details and advantages of Cenestin and also should prove to be a
useful tool for sales representatives."
Cenestin.com was designed and developed by Abelson-Taylor, Inc., a leading
pharmaceutical advertising agency that created the current Cenestin promotional
print materials. Site hosting and technology solutions are provided by Global
Cloud, Ltd., the company that also provides such services for Duramed's
corporate web site.
About Duramed Pharmaceuticals, Inc.
Duramed Pharmaceuticals develops, manufactures and markets prescription drug
products. The company's business strategy emphasizes products with attractive
market opportunities and potentially limited competition due to technological
barriers to entry, focusing on women's health and the hormone replacement
therapy market. The company's mission is to be the premier supplier of solid
oral dose hormone products.
Duramed's containment manufacturing facility for the production of hormones
distinguishes the company from most competitors. The facility incorporates
enclosed product flow and state-of-the-art environmental controls to ensure
purity, stability, and tablet uniformity for its hormone products.
On October 6, 1999, Duramed entered into an alliance with Solvay
Pharmaceuticals, Inc. to jointly promote three of the companies' hormone
products to obstetricians and gynecologists across the United States: Duramed
Pharmaceuticals' Cenestin and Solvay Pharmaceuticals' Estratest(R)1 and
Prometrium(R)2.
The company's stock is traded on Nasdaq using the symbol DRMD. Additional
information about the company can be found on the World Wide Web at
duramed.com and cenestin.com .
About Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc. (http://www.solvaypharmaceuticals-us.com ) based in
Marietta, Ga., is a research-based pharmaceuticals company, active in the
therapeutic areas of cardiology, gastroenterology, mental health and women's
health. Solvay Pharmaceuticals is the second largest pharmaceutical company in
the U.S. hormone replacement therapy market, having advanced from its previous
standing of sixth in the industry in 1996. It is a member of the worldwide
Solvay Group of chemical and pharmaceutical companies, headquartered in
Brussels, Belgium. The Group's members employ some 33,000 people in 46
countries. Its 2000 revenue worldwide was euro 8.8 billion (8.2 billion USD)
from four operating sectors: Chemicals, Plastics, Processing, and
Pharmaceuticals. Additional information about the Group can be found on the
World Wide Web at solvay.com .
1. Estratest is a trademark of Solvay Pharmaceuticals.
2. Prometrium is a trademark of Solvay Pharmaceuticals.
Like all estrogen drug products, CENESTIN(R), and ESTRATEST(R)/ESTRATEST(R) H.S.
Brand Tablets should not be used in women with known or suspected pregnancy,
breast cancer, or estrogen-dependent neoplasia, undiagnosed abnormal genital
bleeding, active thrombophlebitis, or thromboembolic disorders. Estrogens have
been reported to increase the risk of endometrial carcinoma in postmenopausal
women with an intact uterus. The most common adverse events reported in clinical
experience with CENESTIN included headache, insomnia, asthenia, nervousness,
paresthesia, and depression. The most common adverse events reported with
ESTRATEST/ESTRATEST H.S. Brand Tablets included those typical of estrogen
therapy (such as breast tenderness, headache, nausea, edema and abdominal pain)
and of androgen treatment (including hair loss, acne and hirsutism). Common side
effects of PROMETRIUM(R) Capsules are breast tenderness, dizziness, abdominal
bloating, and vaginal discharge. For additional information on CENESTIN,
ESTRATEST Brand Tablets or PROMETRIUM Capsules, please see full prescribing
information.
SOURCE Duramed Pharmaceuticals, Inc.
CONTACT: Duramed Pharmaceuticals, Inc., 513-731-9900; or Lisa
Carlton-Wilson, President of In-Site Communications, Inc.,
212-759-3929, for Duramed Pharmaceuticals, Inc. |
